These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Semi-synthesis, topoisomerase I and kinases inhibitory properties, and antiproliferative activities of new rebeccamycin derivatives. Moreau P; Gaillard N; Marminon C; Anizon F; Dias N; Baldeyrou B; Bailly C; Pierré A; Hickman J; Pfeiffer B; Renard P; Prudhomme M Bioorg Med Chem; 2003 Nov; 11(23):4871-9. PubMed ID: 14604648 [TBL] [Abstract][Full Text] [Related]
25. Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1. Gazzard L; Williams K; Chen H; Axford L; Blackwood E; Burton B; Chapman K; Crackett P; Drobnick J; Ellwood C; Epler J; Flagella M; Gancia E; Gill M; Goodacre S; Halladay J; Hewitt J; Hunt H; Kintz S; Lyssikatos J; Macleod C; Major S; Médard G; Narukulla R; Ramiscal J; Schmidt S; Seward E; Wiesmann C; Wu P; Yee S; Yen I; Malek S J Med Chem; 2015 Jun; 58(12):5053-74. PubMed ID: 25988399 [TBL] [Abstract][Full Text] [Related]
26. Marine pyrrolocarbazoles and analogues: synthesis and kinase inhibition. Deslandes S; Chassaing S; Delfourne E Mar Drugs; 2009 Dec; 7(4):754-86. PubMed ID: 20098609 [TBL] [Abstract][Full Text] [Related]
27. Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin. Bailly C; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M; Waring MJ Mol Pharmacol; 1998 Jan; 53(1):77-87. PubMed ID: 9443934 [TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and biological evaluation of thienopyridinones as Chk1 inhibitors. Song P; Peng P; Han M; Cao X; Ma X; Liu T; Zhou Y; Hu Y Bioorg Med Chem; 2014 Sep; 22(17):4882-92. PubMed ID: 25042558 [TBL] [Abstract][Full Text] [Related]
30. Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue. Bailly C; Qu X; Anizon F; Prudhomme M; Riou JF; Chaires JB Mol Pharmacol; 1999 Feb; 55(2):377-85. PubMed ID: 9927631 [TBL] [Abstract][Full Text] [Related]
31. Synthesis of Cis-fused pyran indolocarbazole derivatives that inhibit FLT3 kinase and the DNA damage kinase, checkpoint kinase 1. Perron-Sierra FM; Kucharkzyk N; Boucley C; Guyard-Daumas C; Sciberras S; Fouache C; Plantier S; Studeny A; Bossard C; Casara PJ; Golsteyn RM Anticancer Agents Med Chem; 2012 Mar; 12(3):194-201. PubMed ID: 22044003 [TBL] [Abstract][Full Text] [Related]
32. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle. Moreau P; Anizon F; Sancelme M; Prudhomme M; Bailly C; Carrasco C; Ollier M; Sevère D; Riou JF; Fabbro D; Meyer T; Aubertin AM J Med Chem; 1998 May; 41(10):1631-40. PubMed ID: 9572888 [TBL] [Abstract][Full Text] [Related]
33. Calories from carbohydrates: energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition. Bailly C; Qu X; Graves DE; Prudhomme M; Chaires JB Chem Biol; 1999 May; 6(5):277-86. PubMed ID: 10322124 [TBL] [Abstract][Full Text] [Related]
34. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Tse AN; Rendahl KG; Sheikh T; Cheema H; Aardalen K; Embry M; Ma S; Moler EJ; Ni ZJ; Lopes de Menezes DE; Hibner B; Gesner TG; Schwartz GK Clin Cancer Res; 2007 Jan; 13(2 Pt 1):591-602. PubMed ID: 17255282 [TBL] [Abstract][Full Text] [Related]
35. Syntheses, biochemical and biological evaluation of staurosporine analogues from the microbial metabolite rebeccamycin. Anizon F; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T; Aubertin AM Bioorg Med Chem; 1998 Sep; 6(9):1597-604. PubMed ID: 9801830 [TBL] [Abstract][Full Text] [Related]
36. Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. Pereira ER; Belin L; Sancelme M; Prudhomme M; Ollier M; Rapp M; Sevère D; Riou JF; Fabbro D; Meyer T J Med Chem; 1996 Oct; 39(22):4471-7. PubMed ID: 8893841 [TBL] [Abstract][Full Text] [Related]
37. Methylenedioxy- and ethylenedioxy-fused indolocarbazoles: potent human topoisomerase I inhibitors and antitumor agents. Zembower DE; Xie Y; Koohang A; Kuffel MJ; Ames MM; Zhou Y; Mishra R; Mar AA; Flavin MT; Xu ZQ Anticancer Agents Med Chem; 2012 Nov; 12(9):1117-31. PubMed ID: 22339065 [TBL] [Abstract][Full Text] [Related]
38. 1,4-Dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: extended exploration on phenyl ring substitutions and preliminary ADME/PK studies. Tong Y; Claiborne A; Pyzytulinska M; Tao ZF; Stewart KD; Kovar P; Chen Z; Credo RB; Guan R; Merta PJ; Zhang H; Bouska J; Everitt EA; Murry BP; Hickman D; Stratton TJ; Wu J; Rosenberg SH; Sham HL; Sowin TJ; Lin NH Bioorg Med Chem Lett; 2007 Jul; 17(13):3618-23. PubMed ID: 17490879 [TBL] [Abstract][Full Text] [Related]
39. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities. Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102 [TBL] [Abstract][Full Text] [Related]
40. Synthesis of C-glycosyl pyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as a scaffold for check point kinase 1 inhibitors. Ichikawa S; Tatebayashi N; Matsuda A J Org Chem; 2013 Dec; 78(23):12065-75. PubMed ID: 24127858 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]